Sign In
Buy AGIO
$30.02
-2.73 (-8.34%)
At Close: Jul 31, 2026
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:01am, Thursday, 05'th Feb 2026
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
07:00am, Monday, 26'th Jan 2026
CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wit
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:36pm, Wednesday, 14'th Jan 2026
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
07:00am, Monday, 12'th Jan 2026
AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter o
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
07:00am, Monday, 05'th Jan 2026
Agios today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares
05:38am, Saturday, 03'rd Jan 2026
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO - Get Free Report) CEO Brian Goff sold 18,703 shares of the company's stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?
09:46am, Friday, 26'th Dec 2025
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
04:56pm, Wednesday, 24'th Dec 2025
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
Agios Pharma Stock: A Buy After FDA Approves Aqvesme
12:48pm, Wednesday, 24'th Dec 2025
Agios Pharmaceuticals upgraded to buy (market perform) after FDA approval of Aqvesme for Alpha- or Beta-Thalassemia, despite boxed warning for liver injury. AGIO's commercial upside from thalassemia i
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label
12:05pm, Wednesday, 24'th Dec 2025
Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.
Here's Why Shares in Agios Pharmaceuticals Popped Today
12:03pm, Wednesday, 24'th Dec 2025
The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a disappoint
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
08:22am, Wednesday, 24'th Dec 2025
Shares of Agios Pharmaceuticals jumped nearly 12% premarket on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder
U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
07:45pm, Tuesday, 23'rd Dec 2025
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemi
Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date
11:26am, Tuesday, 09'th Dec 2025
AGIO faces uncertainty as the FDA misses its Dec. 7 deadline related to the sNDA for Pyrukynd in thalassemia and offers no new timeline.
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
07:00am, Monday, 08'th Dec 2025
Agios today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the sNDA for mitapivat in thalassemia
